Latest Industry Insights

Technology Networks spoke with Michael Yang, president and chief executive officer of ViaCyte, to learn more about the development of a stem cell-derived therapy for the treatment of T1D and the technology behind it.

With a reliance on single-use plastics, significant waste and high energy usage, the carbon footprint of the biopharma industry is large. If we are to accelerate the path to net zero, it is therefore critical to ensure sustainability in science.

As we seek a better tomorrow, here are three predictions from global life science and diagnostics company, PerkinElmer, that will lead to better health outcomes.

Technology Networks spoke to Dr. Mark Kotter, CEO and founder of bit.bio to learn about opti-ox™ and the development, benefits and applications of ioSkeletal Myocytes.

How do we continue to push the boundaries in analytical capabilities, increase confidence in results and apply MS to a wider range of research questions? Technology Networks posed these questions to Rohan Thakur, executive vice president of Life Sciences Mass Spectrometry at Bruker Daltonics, in a recent interview.

Technology Networks spoke to Emily Jackson-Holmes to learn more about the benefits of AAV vectors and reasons for the growing interest in their use.

Technology Networks had the pleasure of speaking with Saul Kato, the CEO of Herophilus, to learn more about how the company plans to reinvent neuro drug discovery, by combining human brain models, scaled biology and machine learning to decode brain disease.

In this interview, Patrick Brown tells us more about the evolution of NanoDrop over the past 20 years, highlights some of the most important improvements during this time and explores what the future may hold for the technology.

Single-cell technologies are transforming our knowledge of human health and disease. In this article, Gary Kruppa outlines the latest advances in single-cell proteomics.

In this interview, Murat Kalayoglu, president and CEO of Cartesian Therapeutics discusses the company’s efforts to develop RNA-modified cell therapies that expand past oncology.